Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Search
Closing healthcare gaps with continued vaccination campaigns
How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Poultry
Poultry
Metabolic Diseases
Metabolic Diseases
Lady, a guide dog in the office
A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Ezabenlimab, PD-1 antibody
Ezabenlimab, PD-1 antibody
Company Culture
Company Culture
Sustainable Development
Sustainable Development
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
A passion for research which addresses unmet medical needs
Eric Haaksma, Head of Global Innovation Animal Health, explains why his professional purpose is rooted in helping drive advancements in scientific research
Newsletter
Newsletter
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim Academy Video 2023
Boehringer Ingelheim’s Academy initiative provides networking opportunities, education and facilitates conversations across the innovation community.
Introducing CIAS
Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Microbial Expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins. Due to the variety of molecular formats that can be synthesised by microbes, microbial manufacturing is characterized by a broad width of production processes.
Transboundary animal diseases and veterinary preparedness
What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.
Covid19 relief program Ghana Cowtribe parasiticides
Boehringer Ingelheim and Cowtribe are kicking off a vital relief initiative in Ghana.
Sites Around the World
Sites Around the World